JP2017522316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522316A5 JP2017522316A5 JP2017502259A JP2017502259A JP2017522316A5 JP 2017522316 A5 JP2017522316 A5 JP 2017522316A5 JP 2017502259 A JP2017502259 A JP 2017502259A JP 2017502259 A JP2017502259 A JP 2017502259A JP 2017522316 A5 JP2017522316 A5 JP 2017522316A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- antibody
- antigen
- binding fragment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025371P | 2014-07-16 | 2014-07-16 | |
| US62/025,371 | 2014-07-16 | ||
| US201462043167P | 2014-08-28 | 2014-08-28 | |
| US62/043,167 | 2014-08-28 | ||
| US201462080725P | 2014-11-17 | 2014-11-17 | |
| US62/080,725 | 2014-11-17 | ||
| US201562132709P | 2015-03-13 | 2015-03-13 | |
| US62/132,709 | 2015-03-13 | ||
| EP15305830.0 | 2015-05-29 | ||
| EP15305830 | 2015-05-29 | ||
| PCT/US2015/040765 WO2016011260A1 (en) | 2014-07-16 | 2015-07-16 | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522316A JP2017522316A (ja) | 2017-08-10 |
| JP2017522316A5 true JP2017522316A5 (enExample) | 2018-08-23 |
| JP6912374B2 JP6912374B2 (ja) | 2021-08-04 |
Family
ID=53365943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502259A Active JP6912374B2 (ja) | 2014-07-16 | 2015-07-16 | 高コレステロール血症を有する高心血管リスク患者を処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160137746A1 (enExample) |
| EP (2) | EP3169362B1 (enExample) |
| JP (1) | JP6912374B2 (enExample) |
| KR (3) | KR20230007538A (enExample) |
| CN (2) | CN114306592A (enExample) |
| AU (1) | AU2015289617B2 (enExample) |
| CA (1) | CA2955304C (enExample) |
| MX (2) | MX378872B (enExample) |
| PL (1) | PL3169362T3 (enExample) |
| RU (1) | RU2723018C2 (enExample) |
| WO (1) | WO2016011260A1 (enExample) |
| ZA (1) | ZA201700196B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| WO2016046684A1 (en) * | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| KR102456731B1 (ko) | 2016-03-03 | 2022-10-24 | 리제너론 파아마슈티컬스, 인크. | Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법 |
| TW202310872A (zh) * | 2017-06-09 | 2023-03-16 | 法商賽諾菲生物技術公司 | 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法 |
| AU2019231703A1 (en) * | 2018-03-06 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Use of PCSK9 inhibitor for reducing cardiovascular risk |
| RS66416B1 (sr) | 2019-01-18 | 2025-02-28 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| BR112022009587A2 (pt) * | 2019-11-18 | 2022-08-02 | Ad Pharmaceuticals Co Ltd | Anticorpo anti-pcsk9 e uso do mesmo |
| JP2023538522A (ja) * | 2020-08-07 | 2023-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法 |
| CN116983434B (zh) * | 2023-09-28 | 2024-03-15 | 康霖生物科技（杭州）有限公司 | 用于基因治疗的核酸构建体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| BR112013018740A2 (pt) * | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| CN103930444B (zh) * | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| CN114642661A (zh) * | 2014-03-17 | 2022-06-21 | 赛诺菲生物技术公司 | 用于降低心血管风险的方法 |
-
2015
- 2015-07-16 EP EP15760317.6A patent/EP3169362B1/en active Active
- 2015-07-16 JP JP2017502259A patent/JP6912374B2/ja active Active
- 2015-07-16 KR KR1020227045465A patent/KR20230007538A/ko not_active Ceased
- 2015-07-16 EP EP20174278.0A patent/EP3753575A1/en not_active Withdrawn
- 2015-07-16 CN CN202111397525.XA patent/CN114306592A/zh active Pending
- 2015-07-16 PL PL15760317T patent/PL3169362T3/pl unknown
- 2015-07-16 CN CN201580049703.6A patent/CN107106678A/zh active Pending
- 2015-07-16 US US14/801,392 patent/US20160137746A1/en not_active Abandoned
- 2015-07-16 AU AU2015289617A patent/AU2015289617B2/en active Active
- 2015-07-16 KR KR1020177004219A patent/KR102482375B1/ko active Active
- 2015-07-16 MX MX2017000628A patent/MX378872B/es unknown
- 2015-07-16 KR KR1020247028498A patent/KR20240132123A/ko not_active Ceased
- 2015-07-16 WO PCT/US2015/040765 patent/WO2016011260A1/en not_active Ceased
- 2015-07-16 CA CA2955304A patent/CA2955304C/en active Active
- 2015-07-16 RU RU2017104799A patent/RU2723018C2/ru active
-
2017
- 2017-01-10 ZA ZA2017/00196A patent/ZA201700196B/en unknown
- 2017-01-13 MX MX2021000289A patent/MX2021000289A/es unknown
-
2019
- 2019-10-24 US US16/662,313 patent/US20200255544A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522316A5 (enExample) | ||
| RU2017104799A (ru) | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию | |
| RU2016142277A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| JP2017528427A5 (enExample) | ||
| JP2016538277A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| JP2017506626A5 (enExample) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| US20230406957A1 (en) | Dosing regimens for use with pcsk9 inhibitors | |
| US20220144969A1 (en) | Methods for reducing cardiovascular risk | |
| ES2914978T3 (es) | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia | |
| ES2773111T3 (es) | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) | |
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2013023499A5 (enExample) | ||
| JP7744190B2 (ja) | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 | |
| JP2016538248A5 (enExample) | ||
| JP2022177142A5 (enExample) | ||
| JP2019509988A5 (enExample) | ||
| JP2019514907A5 (enExample) | ||
| JP2015187125A5 (enExample) | ||
| RU2013156848A (ru) | Лечение антителами против pcsk9 | |
| Liu et al. | A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis | |
| KR20190014117A (ko) | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 | |
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| JP2014511361A5 (enExample) |